COVID-19 Recombinant Protein Vaccine Market Report

Global COVID-19 Recombinant Protein Vaccine Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 09, 2022
  • PAGES：226
  • REPORT CODE：GMM802067
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • COVID-19 Recombinant Protein Vaccine market report explains the definition, types, applications, major countries, and major players of the COVID-19 Recombinant Protein Vaccine market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Johnson & Johnson

    • Suzhou Yuzhibo Biotechnology

    • Sanofi

    • GSK

    • Clover Biopharmaceuticals

    • Novavax

    • Pukang Biologic Technology

    By Type:

    • Being Developed

    • Preclinical

    • Clinical I

    • Clinical II

    By End-User:

    • Pharmaceutical And Biotechnology Companies

    • Hospital

    • Academic And Research Organizations

    • Other

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global COVID-19 Recombinant Protein Vaccine Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 COVID-19 Recombinant Protein Vaccine Outlook to 2028- Original Forecasts

    • 2.2 COVID-19 Recombinant Protein Vaccine Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term COVID-19 Recombinant Protein Vaccine Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global COVID-19 Recombinant Protein Vaccine Market- Recent Developments

    • 6.1 COVID-19 Recombinant Protein Vaccine Market News and Developments

    • 6.2 COVID-19 Recombinant Protein Vaccine Market Deals Landscape

    7 COVID-19 Recombinant Protein Vaccine Raw Materials and Cost Structure Analysis

    • 7.1 COVID-19 Recombinant Protein Vaccine Key Raw Materials

    • 7.2 COVID-19 Recombinant Protein Vaccine Price Trend of Key Raw Materials

    • 7.3 COVID-19 Recombinant Protein Vaccine Key Suppliers of Raw Materials

    • 7.4 COVID-19 Recombinant Protein Vaccine Market Concentration Rate of Raw Materials

    • 7.5 COVID-19 Recombinant Protein Vaccine Cost Structure Analysis

      • 7.5.1 COVID-19 Recombinant Protein Vaccine Raw Materials Analysis

      • 7.5.2 COVID-19 Recombinant Protein Vaccine Labor Cost Analysis

      • 7.5.3 COVID-19 Recombinant Protein Vaccine Manufacturing Expenses Analysis

    8 Global COVID-19 Recombinant Protein Vaccine Import and Export Analysis (Top 10 Countries)

    • 8.1 Global COVID-19 Recombinant Protein Vaccine Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global COVID-19 Recombinant Protein Vaccine Export by Region (Top 10 Countries) (2017-2028)

    9 Global COVID-19 Recombinant Protein Vaccine Market Outlook by Types and Applications to 2022

    • 9.1 Global COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Being Developed Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Preclinical Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Clinical I Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Clinical II Consumption and Growth Rate (2017-2022)

    • 9.2 Global COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Pharmaceutical And Biotechnology Companies Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Academic And Research Organizations Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Other Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise COVID-19 Recombinant Protein Vaccine Market Analysis and Outlook till 2022

    • 10.1 Global COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.2.2 Canada COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.2.3 Mexico COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.3.2 UK COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.3.3 Spain COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.3.4 Belgium COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.3.5 France COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.3.6 Italy COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.3.7 Denmark COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.3.8 Finland COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.3.9 Norway COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.3.10 Sweden COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.3.11 Poland COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.3.12 Russia COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.3.13 Turkey COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.4.2 Japan COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.4.3 India COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.4.4 South Korea COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.4.5 Pakistan COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.4.6 Bangladesh COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.4.7 Indonesia COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.4.8 Thailand COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.4.9 Singapore COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.4.10 Malaysia COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.4.11 Philippines COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.4.12 Vietnam COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.5.2 Colombia COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.5.3 Chile COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.5.4 Argentina COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.5.5 Venezuela COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.5.6 Peru COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.5.7 Puerto Rico COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.5.8 Ecuador COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.6.2 Kuwait COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.6.3 Oman COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.6.4 Qatar COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.6.5 Saudi Arabia COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.6.6 United Arab Emirates COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.7.2 South Africa COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.7.3 Egypt COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.7.4 Algeria COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

      • 10.8.2 New Zealand COVID-19 Recombinant Protein Vaccine Consumption (2017-2022)

    11 Global COVID-19 Recombinant Protein Vaccine Competitive Analysis

    • 11.1 Johnson & Johnson

      • 11.1.1 Johnson & Johnson Company Details

      • 11.1.2 Johnson & Johnson COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Johnson & Johnson COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

      • 11.1.4 Johnson & Johnson COVID-19 Recombinant Protein Vaccine Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Suzhou Yuzhibo Biotechnology

      • 11.2.1 Suzhou Yuzhibo Biotechnology Company Details

      • 11.2.2 Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

      • 11.2.4 Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Sanofi

      • 11.3.1 Sanofi Company Details

      • 11.3.2 Sanofi COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Sanofi COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

      • 11.3.4 Sanofi COVID-19 Recombinant Protein Vaccine Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 GSK

      • 11.4.1 GSK Company Details

      • 11.4.2 GSK COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 GSK COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

      • 11.4.4 GSK COVID-19 Recombinant Protein Vaccine Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Clover Biopharmaceuticals

      • 11.5.1 Clover Biopharmaceuticals Company Details

      • 11.5.2 Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

      • 11.5.4 Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Novavax

      • 11.6.1 Novavax Company Details

      • 11.6.2 Novavax COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Novavax COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

      • 11.6.4 Novavax COVID-19 Recombinant Protein Vaccine Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Pukang Biologic Technology

      • 11.7.1 Pukang Biologic Technology Company Details

      • 11.7.2 Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

      • 11.7.4 Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    12 Global COVID-19 Recombinant Protein Vaccine Market Outlook by Types and Applications to 2028

    • 12.1 Global COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Being Developed Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Preclinical Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Clinical I Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Clinical II Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Pharmaceutical And Biotechnology Companies Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Academic And Research Organizations Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Other Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise COVID-19 Recombinant Protein Vaccine Market Analysis and Outlook to 2028

    • 13.1 Global COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.2.2 Canada COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.2.3 Mexico COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.3.2 UK COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.3.3 Spain COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.3.4 Belgium COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.3.5 France COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.3.6 Italy COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.3.7 Denmark COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.3.8 Finland COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.3.9 Norway COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.3.10 Sweden COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.3.11 Poland COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.3.12 Russia COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.3.13 Turkey COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.4.2 Japan COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.4.3 India COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.4.4 South Korea COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.4.8 Thailand COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.4.9 Singapore COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.4.11 Philippines COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.5.2 Colombia COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.5.3 Chile COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.5.4 Argentina COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.5.6 Peru COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.6.3 Oman COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.6.4 Qatar COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.7.2 South Africa COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.7.3 Egypt COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.7.4 Algeria COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand COVID-19 Recombinant Protein Vaccine Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of COVID-19 Recombinant Protein Vaccine

    • Figure of COVID-19 Recombinant Protein Vaccine Picture

    • Table Global COVID-19 Recombinant Protein Vaccine Import by Region (Top 10 Countries) (2017-2028)

    • Table Global COVID-19 Recombinant Protein Vaccine Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Being Developed Consumption and Growth Rate (2017-2022)

    • Figure Global Preclinical Consumption and Growth Rate (2017-2022)

    • Figure Global Clinical I Consumption and Growth Rate (2017-2022)

    • Figure Global Clinical II Consumption and Growth Rate (2017-2022)

    • Figure Global Pharmaceutical And Biotechnology Companies Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Academic And Research Organizations Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global COVID-19 Recombinant Protein Vaccine Consumption by Country (2017-2022)

    • Table North America COVID-19 Recombinant Protein Vaccine Consumption by Country (2017-2022)

    • Figure United States COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Canada COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Mexico COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Table Europe COVID-19 Recombinant Protein Vaccine Consumption by Country (2017-2022)

    • Figure Germany COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure UK COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Spain COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Belgium COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure France COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Italy COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Denmark COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Finland COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Norway COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Sweden COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Poland COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Russia COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Turkey COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Table APAC COVID-19 Recombinant Protein Vaccine Consumption by Country (2017-2022)

    • Figure China COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Japan COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure India COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure South Korea COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Pakistan COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Indonesia COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Thailand COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Singapore COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Malaysia COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Philippines COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Vietnam COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Table South America COVID-19 Recombinant Protein Vaccine Consumption by Country (2017-2022)

    • Figure Brazil COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Colombia COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Chile COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Argentina COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Venezuela COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Peru COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Ecuador COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Table GCC COVID-19 Recombinant Protein Vaccine Consumption by Country (2017-2022)

    • Figure Bahrain COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Kuwait COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Oman COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Qatar COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Table Africa COVID-19 Recombinant Protein Vaccine Consumption by Country (2017-2022)

    • Figure Nigeria COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure South Africa COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Egypt COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Algeria COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Table Oceania COVID-19 Recombinant Protein Vaccine Consumption by Country (2017-2022)

    • Figure Australia COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Figure New Zealand COVID-19 Recombinant Protein Vaccine Consumption and Growth Rate (2017-2022)

    • Table Johnson & Johnson Company Details

    • Table Johnson & Johnson COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

    • Table Johnson & Johnson COVID-19 Recombinant Protein Vaccine Product Portfolio

    • Table Suzhou Yuzhibo Biotechnology Company Details

    • Table Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

    • Table Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Product Portfolio

    • Table Sanofi Company Details

    • Table Sanofi COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

    • Table Sanofi COVID-19 Recombinant Protein Vaccine Product Portfolio

    • Table GSK Company Details

    • Table GSK COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table GSK COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

    • Table GSK COVID-19 Recombinant Protein Vaccine Product Portfolio

    • Table Clover Biopharmaceuticals Company Details

    • Table Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

    • Table Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Product Portfolio

    • Table Novavax Company Details

    • Table Novavax COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novavax COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

    • Table Novavax COVID-19 Recombinant Protein Vaccine Product Portfolio

    • Table Pukang Biologic Technology Company Details

    • Table Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Main Business and Markets Served

    • Table Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Product Portfolio

    • Figure Global Being Developed Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Preclinical Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinical I Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinical II Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pharmaceutical And Biotechnology Companies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Academic And Research Organizations Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global COVID-19 Recombinant Protein Vaccine Consumption Forecast by Country (2022-2028)

    • Table North America COVID-19 Recombinant Protein Vaccine Consumption Forecast by Country (2022-2028)

    • Figure United States COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe COVID-19 Recombinant Protein Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Germany COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure France COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC COVID-19 Recombinant Protein Vaccine Consumption Forecast by Country (2022-2028)

    • Figure China COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure India COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table South America COVID-19 Recombinant Protein Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Brazil COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC COVID-19 Recombinant Protein Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Bahrain COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa COVID-19 Recombinant Protein Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Nigeria COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania COVID-19 Recombinant Protein Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Australia COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand COVID-19 Recombinant Protein Vaccine Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US